Xencor Inc
NASDAQ:XNCR 3:59:45 PM EDT
| Market Cap (Intraday) | 2.45B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $42.32 |
| 50-Day MA | $46.04 |
| 200-Day MA | $41.12 |
Xencor, Inc. Stock, NASDAQ:XNCR
111 West Lemon Avenue, 2nd floor, Monrovia, California 91016
United States of America
Phone: +1.626.305.5900
Number of Employees: 166
Description
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.